Meta-analysis of Efficacy of Topotecan

Completed

• Conditions: Cervical Intraepithelial Neoplasia
• Interventions: Drug: paclitaxel; Drug: cisplatin; Drug: topotecan

• Registration Number: NCT01160185
• Lead Sponsor: GlaxoSmithKline

Brief Summary

This meta-analysis was conducted to investigate the efficacy of Topotecan and other treatments for recurrent and stage IVB carcinoma of the cervix

Detailed Description

Studies included in the meta-analysis were: GOG-0179, GOG-0204 \& GOG-0169

Study Timeline

• Study Start: 2009-06
• Primary Completion: 2009-07
• Study Completion: 2009-07
• Status Verified: 2010-07
• Study First Submitted: 2010-07-08
• Study First Submitted QC: 2010-07-08
• Last Update Submitted: 2010-07-08
• Study First Posted: 2010-07-12
• Last Update Posted: 2010-07-12

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 1

Inclusion Criteria

• Randomised Clinical Trials or systematic reviews or meta-analyses
• Treatment with topotecan or platinum-based single and combination regimens in female patients of any race with cancer of the cervix recurrent after radiotherapy or stage IVB disease

Exclusion Criteria

• None

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
cisplatin + paclitaxel	cisplatin	-
cisplatin	cisplatin	-
cisplatin + topotecan	cisplatin	-
cisplatin + topotecan	topotecan	-
cisplatin + paclitaxel	paclitaxel	-

Primary Outcome Measures

Name	Time	Method
Survival	12 months